Vaxcyte, Inc. logo

Vaxcyte, Inc. (PCVX)

Market Closed
17 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
56. 20
+0.16
+0.2855%
$
8.12B Market Cap
- P/E Ratio
- Div Yield
1.13M Volume
-3.49 Eps
$ 56.04
Previous Close
Add Transaction
Day Range
54.59 57.86
Year Range
29.08 65
Want to track PCVX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial.

Reuters | 1 year ago
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.

Zacks | 1 year ago
Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower

Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower

Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older.

Schaeffersresearch | 1 year ago
Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar to rival Pfizer's shot.

Reuters | 1 year ago
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market

Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market

Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.

Investors | 1 year ago
Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Vaxcyte Inc.'s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older.

Marketwatch | 1 year ago
Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

The consensus price target hints at a 25.2% upside potential for Vaxcyte (PCVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 1 year ago
Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice

Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice

Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 year ago